Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitotic progression refers to the sequence of events by which a eukaryotic cell passes through the stages of mitosis—prophase, prometaphase, metaphase, anaphase, and telophase—resulting in the equal segregation of duplicated chromosomes into two genetically identical daughter nuclei[1][2][3]. This process is essential for growth, tissue repair, and maintenance in multicellular organisms. Dysregulation or errors in mitotic progression are associated with diseases such as cancer due to uncontrolled cell proliferation[3]. However, "mitotic progression" itself is not a specific molecule or receptor but rather describes a cellular process involving numerous proteins and regulatory pathways. Notes on correctness ("is_incorrect"): The term "mitotic progression" does not refer to a single molecular target such as an enzyme or receptor; instead it describes a biological process. Therefore it cannot be considered a canonical therapeutic target on its own[1][2][3]. If you are seeking information about druggable targets involved in this process (such as Aurora kinases or Polo-like kinases), those should be specified individually.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitotic progression.